How Will the Market React to Jazz Pharmaceuticals PLC (JAZZ) Stock Getting a Bearish Rating

The market has been down on Jazz Pharmaceuticals PLC (JAZZ) stock recently. JAZZ gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Jazz Pharmaceuticals PLC has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on JAZZ!

See Full JAZZ Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With JAZZ Stock Today?

Jazz Pharmaceuticals PLC (JAZZ) stock has gained 1.48% while the S&P 500 is down -0.63% as of 2:44 PM on Wednesday, May 11. JAZZ has risen $2.13 from the previous closing price of $144.03 on volume of 224,255 shares. Over the past year the S&P 500 has fallen -5.07% while JAZZ is down -17.00%. JAZZ lost -$7.52 per share in the over the last 12 months.

More About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. Click Here to get the full Stock Report for Jazz Pharmaceuticals PLC stock.